Investor Presentation

October 29, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) (DSaClRalI PSt CreOeDt,E : 539871) B andra (E), Mumbai - 400051 Mumbai- 400001 Sub: Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2026 Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, October 29, 2026, 06:00 P.M. (IST) We are enclosing - a copy of the Investor presentation to be made at the earnings conference call for analysts and investors, to be held today, i.e. at on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. The same is also being made available on the Company’s website https://investor.thyrocare.com/ We request you to please take the same on record. T hyrocare Technologies Limited, Y ours Faithfully, F or Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a From Routine Remarkable: The Next Frontier of Diagnostics Q2 FY27 Earnings Presentation Safe Harbour Statement This presentation has been prepared by Thyrocare Technologies Limited ("Thyrocare"/"TTL"/"Company") for general information purposes only. While reasonable care has been taken in preparing the information, the Company makes no representation or warranty, express or implied, as to its accuracy, completeness or reliability, and accepts no liability for any loss arising from the use of or reliance on this presentation. This presentation contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates"or other words of similar meaning. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Actual results may differ materially due to various risks, uncertainties and other factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contents Particulars Page No Who we are 4 Our Journey 7 Q2 FY27 Key Performance Metrics 9 Other Highlights of Q2 FY27 11 Q2 FY27 Financial Performance 16 Divestment impact 28 Going forward –Key Pillars of Growth 31 Contents Who we are Thyrocare - Making good quality diagnostics affordable to all since 1996 Global in our reach, To make good quality excellence in our experience diagnostics affordable to all 49 1,420+ 96% 12,911 Pan India Home Total Labs Comprehensive Samples Quarterly (Incl 1 Test Menu Processed at Active Service International NABL Labs Franchisee Lab in Tanzania) Trusted Brands Pan-India presence with network of 49 labs Region-wise Region-wise India Lab count India Pathology revenue mix%^ 9 21% 12 26% East West 10 North 24% South 02 CPL 02 ZPL Central Processing Labs Zonal Processing Labs 26 RPL 06 SPL Regional Processing Labs Satellite Processing Labs 08 Hybrid 04 Acquired Hybrid Labs Acquired Labs +1 International lab –Tanzania ^ Basis Lab Processing 6 Contents Our Journey Improvement across quality, reliability and reach over last 5 years Active H Lab Network Test Menu C Franchisee E 49 Labs 12,911 1,420+ R 17 3,600+ 275+ LaFYb2s021 Q2FY27 FY2021 Q2FY27 FY2021 Q2FY27 (Inc.1 international lab in Tanzania) T Lab Phlebo Top of the line L Turnaround On-time Arrival lab equipment time I L ~99% 3.49 hours ~INR 275 Crores (60 Min slot adherence) Invested Since FY21 Y NABL Samples T Pathologists Complaints per I Processed L Million tests 108+ U <10 96% Q FY2021 Q2FY27 Samples Processed at NABL Labs Contents Q2 FY27 Key Performance Metrics Q2 FY27 - Delivered 25% YoY revenue and 26% YoY PAT^ growth with highest quality standards FINANCIAL OPERATIONAL QUALITY Consolidated revenue 271 Cr +25% 12,911 96% Standalone revenue Quarterly active franchisees Samples processed in NABL labs 256 Cr +27% Franchisee revenue 159 Cr +27% 5.7 Mn 61.6 Mn* Partnership revenue +14% YoY +27% YoY 84 Cr +28% Patients Tests conducted +25% +26% 1,420+ 2.9 24% down YoY Test menu offerings Complaints per Mn tests EBITDA YoY PAT^ YoY ^ PAT before exceptions relating to impairment of NHL * Definition of test conducted revised from Q1 FY27 to exclude calculated parameters. Restated numbers from previous quarters: -FY26 Q1 –43.1 Mn, Q2 –48.4 Mn, Q3 –44.5 Mn, Q4 –52.7 Mn & FY25 Q1 –34.7 Mn, Q2 –39.9 Mn, Q3 –36.6 Mn, Q4 –41.0 Mn Contents Other Highlights of Q2 FY27 We have launched India's first pregnancy kit with a lab test in every pack 5 new labs launched this quarter Launched 4 new Regional Processing Laboratory in Asansol, Nasik, Madurai and Jabalpur along with a Hybrid lab in Jamshedpur. These facilities will strengthen our testing network and improve turnaround times in nearby catchment areas Jabalpur – July 2026 Madurai - August 2026 Nasik - September 2026 Asansol - September 2026 Jamshedpur - Sept 2026 Strengthening our relationships with channel partners In Q2 FY27, Thyrocare conducted franchisee meetings, capturing feedback from franchisees across those locations. These insights were used to strengthen processes, service delivery, and overall quality outcome Varanasi Franchisee Meet Lucknow Franchisee Meet Strengthening our relationships with Doctors In Q2 FY27, We conducted 45 Doctor meetings, capturing feedback from 100+ doctors across those locations. These insightswere used to strengthen processes, service delivery, and overall quality outcome Lucknow Chennai Hyderabad Ranchi Pune Mumbai Contents Q2 FY27 Financial Performance Financial Performance Q2 & H1 FY27 Q2 FY27 H1 FY27 YoY TTL Consolidated +25.1% +24.7% Revenue YoY Pathology Revenue +26.7% +26.4% YoY EBITDA +25.0% +29.2% YoY PAT^ +25.7% +29.7% EBITDA Margin 33.0% 32.6% PAT^ % 22.2% 21.8% ^ PAT before exceptions relating to impairment of NHL 25.1% YoY revenue growth in overall business and 25.0% YoY growth in EBITDA in Q2 FY27 Consolidated Revenue (INR Cr) EBITDA (INR Cr) +25.1% +25.0% 270.8 89.3 240.0 216.5 223.9 75.1 77.3 71.5 195.5 57.6 257.2 85.7 226.5 202.3 183.1 211.5 68.6 72.2 74.7 56.7 14.2 12.4 12.5 13.5 13.6 2.9 0.9 2.9 2.7 3.6 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 EBITDA% 33.0% 29.5% 33.5% 32.2% 33.0% YoY Growth% Pathology +25.7% YoY Growth% Radiology -4.3% Pathology + 24.7% Radiology + 25.8% Radiology Business consists of Nuclear healthcare and Pulse Hi tech businesses 18 Consistent and healthy growth across business verticals Pathology Revenue (INR Cr)* Pathology Vials (Lakhs)* YoY% YoY% 62.9 159.2 +26.9% 57.2 +22.3% 142.8 51.4 52.5 46.4 125.4 127.6 112.2 83.9 30.3 71.6 71.0 +27.9% 25.8 26.6 +32.1% 65.6 60.1 22.9 22.6 11.2 10.2 11.5 11.8 13.1 1.8 1.7 2.0 2.1 2.3 +16.8% +28.3% Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 76.1 70.7 80.3 85.9 95.4 202.2 Cr 182.5 Cr 210.7 Cr 225.6 Cr 256.3 Cr +26.7% Lakhs Lakhs Lakhs Lakhs Lakhs +25.4% *Above numbers do not include Tanzania business 19 Strong and consistent growth outlined by key metrics Tests performed (Mn) ^ Patients (Mn) Quarterly active franchisees (#) +27.4% +13.4% +27.1% 61.6 5.7 12,911 48.4 4.4 10,159 39.9 8,446 Q2FY25 Q2FY26 Q2FY27 Q2FY25 Q2FY26 Q2FY27 Q2FY25 Q2FY26 Q2FY27 Revenue per test (INR) *^ Revenue per patient (INR) Tests per patient (#) ^ -2.3% +9.8% +12.3% 39.6 40.8 39.8 433 10.9 Q2FY25 Q2FY26 Q2FY27 Q2FY25 Q2FY26 Q2FY27 Q2FY25 Q2FY26 Q2FY27 * Excludes material and others revenue ^Definition of test conducted revised from Q1 FY27 to exclude calculated parameters. Restated numbers from previous quarters: -FY26 Q1 –43.1 Mn, Q2 –48.4 Mn, Q3 –44.5 Mn, Q4 –52.7 Mn & -FY25 Q1 [Showing first 8,000 characters — download PDF for full document]